Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 3/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.39 |
| ▸ | NPY2R | P49146 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17126 | 0.91 | RORC (0.54) | RORC | |
| SCHEMBL12089736 | 0.87 | GPR119 (0.40) | RORCGPR119 | |
| SCHEMBL12090314 | 0.82 | GPR119 (0.40) | RORCNR1H2GPR119 | |
| SCHEMBL12090279 | 0.82 | GPR119 (0.42) | GPR119 | |
| SCHEMBL12090084 | 0.82 | RORC (0.41) | RORCGPR119KDM4EPKM | |
| SCHEMBL31484639 | 0.81 | GPR119 (0.52) | GPR119STSKDM4EPKM | |
| SCHEMBL12090271 | 0.81 | PARP1 (0.43) | RORCGPR119STSKDM4EPKM | |
| SCHEMBL18319 | 0.77 | GCKR (0.51) | RORC | |
| SCHEMBL18549 | 0.77 | RORC (0.53) | RORCGPR119 | |
| SCHEMBL21360338 | 0.77 | GPR119 (0.52) | NR1H2GPR119STSKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | GCKR, GCK, SLC5A2 | RORC 2301/4885NR1H2 1489/4885NR1H3 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.